GlassScriptPhysician profile
Rebecca Leynes
NPI 1063643740
$10,702.72
in general payments reported to CMS, 2019-2025
31 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,276 · 2022: $2,192 · 2023: $2,268 · 2024: $2,141 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,721 · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,720.96 |
| Education | $513.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,324.85 | 2021-2025 | |
| Janssen Biotech, INC. | $1,671.30 | 2021-2025 | Tremfya |
| Genzyme Corporation | $1,262.80 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $997.01 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $594.07 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $506.03 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $490.45 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $473.14 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Botanix Sb INC | $348.91 | 2025 | Sofdra |
| Amgen INC. | $294.08 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $257.78 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.64 | 2023-2025 | Spevigo |
| Ucb, INC. | $213.24 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $118.66 | 2021-2022 | |
| Dermavant Sciences, INC. | $107.11 | 2022-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $101.96 | 2023-2025 | Affinity, Puraply |
| Galderma Laboratories, L.P. | $100.73 | 2022-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Epi Health, LLC | $90.54 | 2022 | |
| Incyte Corporation | $88.49 | 2022-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $86.62 | 2024 | Tremfya |
| Leo Pharma INC. | $56.92 | 2022-2023 | Adbry |
| Cipher Pharmaceuticals US LLC | $27.08 | 2025 | Spinosad, Natroba |
| Vyne Pharmaceuticals INC. | $25.97 | 2021 | |
| Journey Medical Corporation | $24.90 | 2023 | |
| Almirall LLC | $22.30 | 2022 | |
| Lnhc, INC | $21.73 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $20.53 | 2025 | Zoryve |
| Organon LLC | $20.37 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $17.78 | 2023 | Xtrac |
| Smith+Nephew, INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Leynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.